The company said worldwide revenue for Q3 2025 grew 22% on a reported basis to $1.209 billion, compared with $994.2 million for Q3 2024. Organic growth was 20%.

1. 01

   The company said worldwide revenue for Q3 2025 grew 22% on a reported basis to $1.209 billion, compared with $994.2 million for Q3 2024. Organic growth was 20%.

2. 02

   The company said GAAP operating income for Q3 2025 rose to $242.5 million (20.1% of revenue) from $152.0 million (15.3%) for Q3 2024. Non-GAAP operating income was $272.9 million (22.6% of reported revenue).

3. 03

   The company reported GAAP net income for Q3 2025 of $283.8 million ($0.70 per diluted share) and non-GAAP net income of $242.5 million ($0.61 per diluted share). It said non-GAAP net income excludes income from equity investments of $82.7 million.

4. 04

   The company said it presented its full-year 2025 revenue outlook at $4.630 to $4.650 billion (approximately 15% growth). As of September 30, 2025, Dexcom held $3.32 billion in cash, cash equivalents and marketable securities, and its revolving credit facility was undrawn.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.